• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

哮喘门诊治疗的估计费用:一项真实世界研究

Estimated cost of asthma in outpatient treatment: a real-world study.

作者信息

Costa Eduardo, Caetano Rosangela, Werneck Guilherme Loureiro, Bregman Maurício, Araújo Denizar Vianna, Rufino Rogério

机构信息

Universidade do Estado do Rio de Janeiro. Faculdade de Ciências Médicas. Departamento de Medicina Interna. Rio de Janeiro, RJ, Brasil.

Universidade do Estado do Rio de Janeiro. Instituto de Medicina Social. Departamento de Política, Planejamento e Administração em Saúde. Rio de Janeiro, RJ, Brasil.

出版信息

Rev Saude Publica. 2018 Apr 9;52:27. doi: 10.11606/S1518-8787.2018052000153.

DOI:10.11606/S1518-8787.2018052000153
PMID:29641652
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5893272/
Abstract

OBJECTIVE

To estimate the cost of diagnosis and treatment of asthma.

METHODS

We used the perspective of society. We sequentially included for 12 months, in 2011-2012, 117 individuals over five years of age who were treated for asthma in the Pneumology and Allergy-Immunology Services of the Piquet Carneiro Polyclinic, Universidade do Estado do Rio de Janeiro. All of them were interviewed twice with a six-month interval for data collection, covering 12 months. The cost units were identified and valued according to defined methods. We carried out a sensitivity analysis and applied statistical methods with a significance level of 5% for cost comparisons between subgroups.

RESULTS

The study consisted of 108 patients, and 73.8% of them were women. Median age was 49.5 years. Rhinitis was present in 83.3% of the individuals, and more than half were overweight or obese. Mean family income was U$915.90/month (SD = 879.12). Most workers and students had absenteeism related to asthma. Total annual mean cost was U$1,291.20/patient (SD = 1,298.57). The cost related to isolated asthma was U$1,155.43/patient-year (SD = 1,305.58). Obese, severe, and uncontrolled asthmatic patients had higher costs than non-obese, non-severe, and controlled asthmatics, respectively. Severity and control level were independently associated with higher cost (p = 0.001 and 0.000, respectively). The direct cost accounted for 82.3% of the estimated total cost. The cost of medications for asthma accounted for 62.2% of the direct costs of asthma.

CONCLUSIONS

Asthma medications, environmental control measures, and long-term health leaves had the greatest potential impact on total cost variation. The results are an estimate of the cost of treating asthma at a secondary level in the Brazilian Unified Health System, assuming that the treatment used represents the ideal approach to the disease.

摘要

目的

评估哮喘的诊断和治疗成本。

方法

我们采用社会视角。在2011年至2012年期间,连续12个月纳入了里约热内卢州立大学皮克泰·卡内罗综合诊所呼吸科和过敏 - 免疫科接受哮喘治疗的117名5岁以上个体。他们均接受了两次间隔六个月的数据收集访谈,涵盖12个月。根据既定方法确定并评估成本单位。我们进行了敏感性分析,并应用统计方法,在亚组间成本比较时显著性水平设定为5%。

结果

该研究包括108名患者,其中73.8%为女性。中位年龄为49.5岁。83.3%的个体患有鼻炎,超过一半的人超重或肥胖。家庭月平均收入为915.90美元(标准差 = 879.12)。大多数工人和学生因哮喘缺勤。患者年总平均成本为1291.20美元/患者(标准差 = 1298.57)。单纯哮喘相关成本为1155.43美元/患者 - 年(标准差 = 1305.58)。肥胖、重度和未控制的哮喘患者的成本分别高于非肥胖、非重度和已控制的哮喘患者。严重程度和控制水平分别与较高成本独立相关(p值分别为0.001和0.000)。直接成本占估计总成本的82.3%。哮喘药物成本占哮喘直接成本的62.2%。

结论

哮喘药物、环境控制措施和长期病假对总成本变化的潜在影响最大。这些结果是对巴西统一卫生系统二级水平哮喘治疗成本的估计,假设所采用的治疗方法代表了该疾病的理想治疗方式。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0953/5893272/b880fb9aac23/0034-8910-rsp-S1518-52-87872018052000153-gf01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0953/5893272/b880fb9aac23/0034-8910-rsp-S1518-52-87872018052000153-gf01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0953/5893272/b880fb9aac23/0034-8910-rsp-S1518-52-87872018052000153-gf01.jpg

相似文献

1
Estimated cost of asthma in outpatient treatment: a real-world study.哮喘门诊治疗的估计费用:一项真实世界研究
Rev Saude Publica. 2018 Apr 9;52:27. doi: 10.11606/S1518-8787.2018052000153.
2
Economic impact of severe asthma in Spain: multicentre observational longitudinal study.西班牙重度哮喘的经济影响:多中心观察性纵向研究
J Asthma. 2019 Aug;56(8):861-871. doi: 10.1080/02770903.2018.1499035. Epub 2018 Oct 9.
3
[Economic cost of treating the patient with asthma in Spain: the AsmaCost study].[西班牙哮喘患者的治疗经济成本:阿斯马成本研究]
Arch Bronconeumol. 2009 Oct;45(10):481-6. doi: 10.1016/j.arbres.2009.04.006. Epub 2009 Jun 13.
4
[Cost of asthma therapy in relation to severity. An empirical study].[哮喘治疗成本与严重程度的关系。一项实证研究]
Med Klin (Munich). 1996 Oct 15;91(10):670-6.
5
COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada.沙美特罗/丙酸氟替卡松联合制剂(舒利迭(®))治疗加拿大控制不佳哮喘的成本效益分析
Respir Med. 2014 Sep;108(9):1292-302. doi: 10.1016/j.rmed.2014.06.005. Epub 2014 Jun 25.
6
The Cost of Asthma Treatment in Phramongkutlao Hospital: Population-Based Study in Adults.诗里拉吉医院哮喘治疗费用:基于人群的成人研究
J Med Assoc Thai. 2016 Jan;99(1):51-7.
7
Uncontrolled asthma in a commercially insured population from 2002 to 2007: trends, predictors, and costs.2002年至2007年商业保险人群中未控制的哮喘:趋势、预测因素及成本
J Asthma. 2010 Jun;47(5):574-80. doi: 10.3109/02770901003792841.
8
Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting.在巴西医疗环境中,奥马珠单抗附加于标准治疗方案用于控制不佳的重度过敏性哮喘患者的成本效益分析。
J Med Econ. 2017 Aug;20(8):832-839. doi: 10.1080/13696998.2017.1333513. Epub 2017 Jun 14.
9
Economic costs for adult asthmatics according to severity and control status in Korean tertiary hospitals.韩国三级医院中成年哮喘患者按严重程度和控制状态划分的经济成本。
J Asthma. 2012 Apr;49(3):303-9. doi: 10.3109/02770903.2011.641046. Epub 2011 Dec 21.
10
The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry.英国治疗严重难治性哮喘的成本:英国胸科学会难治性哮喘注册研究的经济分析。
Thorax. 2015 Apr;70(4):376-8. doi: 10.1136/thoraxjnl-2013-204114. Epub 2014 Jun 10.

引用本文的文献

1
Epidemiology of patients with asthma in Korea: Analysis of the NHISS database 2006-2015.韩国哮喘患者的流行病学:2006 - 2015年韩国国家健康保险服务(NHISS)数据库分析
World Allergy Organ J. 2023 Apr 19;16(4):100768. doi: 10.1016/j.waojou.2023.100768. eCollection 2023 Apr.
2
The economic impact of asthma on private healthcare system in Brazil: Economic impact of asthma in Brazil.巴西私人医疗体系中哮喘的经济负担:巴西哮喘的经济负担。
Medicine (Baltimore). 2023 Mar 24;102(12):e33077. doi: 10.1097/MD.0000000000033077.
3
Economic burden of severe asthma treatment: A real-life study.

本文引用的文献

1
Cost of severe asthma in Brazil-systematic review.巴西重度哮喘的成本——系统评价
J Asthma. 2016 Dec;53(10):1063-70. doi: 10.3109/02770903.2016.1171338. Epub 2016 Apr 26.
2
ERICA: prevalence of asthma in Brazilian adolescents.埃丽卡:巴西青少年哮喘的患病率。
Rev Saude Publica. 2016 Feb;50 Suppl 1(Suppl 1):13s. doi: 10.1590/S01518-8787.2016050006682. Epub 2016 Feb 23.
3
Asthma in Latin America.拉丁美洲的哮喘
重度哮喘治疗的经济负担:一项真实世界研究。
World Allergy Organ J. 2022 Jul 4;15(7):100662. doi: 10.1016/j.waojou.2022.100662. eCollection 2022 Jul.
4
Molecular mechanisms of An-Chuan Granule for the treatment of asthma based on a network pharmacology approach and experimental validation.基于网络药理学方法和实验验证的安喘颗粒治疗哮喘的分子机制。
Biosci Rep. 2021 Mar 26;41(3). doi: 10.1042/BSR20204247.
5
Yes, there really are individuals with severe asthma: the importance and limitations of data obtained from specialized centers.是的,确实存在重度哮喘患者:来自专业中心的数据的重要性及局限性。
J Bras Pneumol. 2020 Jun 15;46(3):e20200191. doi: 10.36416/1806-3756/e20200191.
6
2020 Brazilian Thoracic Association recommendations for the management of asthma.2020 年巴西胸科协会哮喘管理建议。
J Bras Pneumol. 2020 Mar 2;46(1):e20190307. doi: 10.1590/1806-3713/e20190307. eCollection 2020.
7
Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry.口服糖皮质激素相关不良事件的隐性成本:一项应用于意大利重症哮喘网络(SANI)登记处真实数据的药物经济学评估。
World Allergy Organ J. 2019 Jan 26;12(1):100007. doi: 10.1016/j.waojou.2018.12.001. eCollection 2019.
Thorax. 2015 Sep;70(9):898-905. doi: 10.1136/thoraxjnl-2015-207199. Epub 2015 Jun 23.
4
The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry.英国治疗严重难治性哮喘的成本:英国胸科学会难治性哮喘注册研究的经济分析。
Thorax. 2015 Apr;70(4):376-8. doi: 10.1136/thoraxjnl-2013-204114. Epub 2014 Jun 10.
5
Asthma and the socio-economic reality in Brazil.哮喘与巴西的社会经济现实。
World Allergy Organ J. 2013 Nov 12;6(1):20. doi: 10.1186/1939-4551-6-20.
6
State of world allergy report 2008: allergy and chronic respiratory diseases.2008 年世界过敏状况报告:过敏和慢性呼吸道疾病。
World Allergy Organ J. 2008 Jun;1(6 Suppl):S4-S17. doi: 10.1097/WOX.0b013e31817ff995.
7
Asthma and obesity.哮喘和肥胖。
Clin Exp Allergy. 2013 Jan;43(1):8-21. doi: 10.1111/j.1365-2222.2012.04040.x.
8
The cost of persistent asthma in Europe: an international population-based study in adults.欧洲持续性哮喘的成本:一项基于成年人的国际人群研究。
Int Arch Allergy Immunol. 2013;160(1):93-101. doi: 10.1159/000338998. Epub 2012 Sep 1.
9
Ten-year trends in prevalence of asthma in adults in southern Brazil: comparison of two population-based studies.巴西南部成年人哮喘患病率的 10 年趋势:两项基于人群的研究比较。
Cad Saude Publica. 2012 Jan;28(1):135-44. doi: 10.1590/s0102-311x2012000100014.
10
The burden of adult asthma in the United States: evidence from the Medical Expenditure Panel Survey.美国成人哮喘负担:来自医疗支出面板调查的证据。
J Allergy Clin Immunol. 2011 Feb;127(2):363-369.e1-3. doi: 10.1016/j.jaci.2010.10.042.